# Regeneron Pharmaceuticals Inc.

Canonical: https://abierto.us/vendors/regeneron-pharmaceuticals-inc-n3f9mh7e6hd6

- UEI: N3F9MH7E6HD6
- CAGE: 544P9
- Location: Tarrytown, NY
- Awards in window: 5 (22 transactions), -$329,361,115 obligated, January 7, 2025 to July 30, 2026

## Awarding agencies

- Department of Veterans Affairs: 2 awards, $0
- Office of Assistant Secretary for Preparedness and Response: 3 awards, -$329,361,115

## Industries

- 325412 Pharmaceutical Preparation Manufacturing: $0
- 541711 Professional, Scientific, and Technical Services: -$329,361,115

## Competition

- Full and Open Competition: 4 awards
- Not Competed: 1 awards

## Largest awards

- HHSO100201700016C (definitive contract): $2,684,549, Barda - Aspr / Daappo / Barda DCMA. No Cost Mod to Revise the Contract Sections: Article B.4 and F.4. https://www.usaspending.gov/award/CONT_AWD_HHSO100201700016C_7505_-NONE-_-NONE-/
- 36E79721A0023: $0, Nac Pharmaceuticals. Exercise Option Year 4. https://www.usaspending.gov/award/CONT_IDV_36E79721A0023_3600/
- 36F79721D0169: $0, Nac Federal Supply Schedule. FSS. https://www.usaspending.gov/award/CONT_IDV_36F79721D0169_3600/
- HHSO100201600023C (definitive contract): -$337,504, Barda - Aspr / Daappo / Barda DCMA. Regeneron Anti-Mers Antibody Therapeutics Program Development. https://www.usaspending.gov/award/CONT_AWD_HHSO100201600023C_7505_-NONE-_-NONE-/
- HHSO100201700020C (definitive contract): -$331,708,160, Barda - Aspr / Daappo / Barda DCMA. E.O. Radical Transparency About Wasteful Spending. Descope Mod Iaw with RTWS to Remove Unused Funds from Multiple Clins Resulting in a De-Obligation of $331,708,160.10 and a Reduction in Total Contract Value of $331,708,160.10.. https://www.usaspending.gov/award/CONT_AWD_HHSO100201700020C_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/regeneron-pharmaceuticals-inc-n3f9mh7e6hd6.